Athna Biotech, Inc.
Publicly observedAthens, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Athens | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Athna Biotech, Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | LBCCTS71U2N4 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant5 May 2022Publicly observed
NIH SBIR/STTR award: Development of a salt-based nanomedicine for non-muscle invasive bladder cancer
USD 937,492.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
- Grant14 Jun 2021Publicly observed
NIH SBIR/STTR award: Development of a radiation-activatable nanoparticle for lung cancer therapy
USD 1,098,560.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
- Grant14 Jun 2021Publicly observed
NIH SBIR/STTR award: Development of a radiation-activatable nanoparticle for lung cancer therapy
USD 901,390.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.